Get the Stockscreener App
54.81
3.24%
-1.7787
Apogee Therapeutics Inc stock is traded at $54.81, with a volume of 477.24K.
It is down -3.24% in the last 24 hours and up +37.30% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$56.59
Open:
$56.98
24h Volume:
477.24K
Relative Volume:
0.73
Market Cap:
$2.53B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-19.90
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
-2.62%
1M Performance:
+37.30%
6M Performance:
+36.48%
1Y Performance:
+0.49%
1-Day Range:
$53.53
$58.36
1-Week Range:
$53.53
$58.36
52-Week Range:
$26.20
$63.50
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
54.82 | 3.83B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Apogee Therapeutics stock initiated with Buy rating at Craig-Hallum - Investing.com
Apogee Therapeutics stock price target raised by RBC Capital to $70 - Investing.com Nigeria
Apogee Therapeutics to Participate in Upcoming Conferences - The Manila Times
Apogee Therapeutics (NASDAQ: APGE) to join five fireside chats; webcast available - Stock Titan
How to use Fibonacci retracement on Apogee Therapeutics Inc.2025 Valuation Update & High Conviction Buy Zone Alerts - newser.com
Is Apogee Therapeutics Inc. stock a dividend growth opportunityJuly 2025 Price Swings & Reliable Breakout Forecasts - newser.com
Will breakout in Apogee Therapeutics Inc. lead to full recoveryProfit Target & Trade Opportunity Analysis - newser.com
Detecting support and resistance levels for Apogee Therapeutics Inc.Jobs Report & Verified Momentum Stock Ideas - newser.com
Real time scanner hits for Apogee Therapeutics Inc. explainedJuly 2025 WrapUp & Reliable Entry Point Trade Alerts - newser.com
How to read the order book for Apogee Therapeutics Inc.Rate Cut & Fast Exit and Entry Trade Guides - newser.com
Moody Aldrich Partners LLC Takes $939,000 Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Jennison Associates LLC Sells 23,391 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
How to track smart money flows in Apogee Therapeutics Inc.July 2025 Technicals & Daily Entry Point Alerts - newser.com
Why Apogee Therapeutics (APGE) Is Up 6.1% After $300 Million Raise to Advance APG777 - Yahoo Finance
Can volume confirm reversal in Apogee Therapeutics Inc.Portfolio Value Report & Safe Entry Momentum Tips - newser.com
Using data filters to optimize entry into Apogee Therapeutics Inc.July 2025 EndofMonth & Free Low Drawdown Momentum Trade Ideas - newser.com
How to integrate Apogee Therapeutics Inc. into portfolio analysis tools - newser.com
Apogee Therapeutics: Plan To Take Standard-Of-Care Status From Dupixent Is Risky (APGE) - Seeking Alpha
Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade - sharewise.com
Mizuho Securities Keeps Their Buy Rating on Apogee Therapeutics (APGE) - The Globe and Mail
Will Apogee Therapeutics Inc. stock split attract more investorsPortfolio Value Report & Growth Focused Entry Reports - newser.com
Apogee Therapeutics’ APG777 Study: A Potential Breakthrough in Atopic Dermatitis Treatment - TipRanks
Apogee Therapeutics’ New Study on Atopic Dermatitis: What Investors Need to Know - TipRanks
Apogee Therapeutics’ Promising Update on Long-term APG777 Study for Atopic Dermatitis - TipRanks
Why Apogee Therapeutics Inc. stock is recommended by analystsJuly 2025 Catalysts & Accurate Entry/Exit Alerts - fcp.pa.gov.br
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):